(Q73289992)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Systematic, immediate in-hospital initiation of lipid-lowering drugs during acute coronary events improves lipid control (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Nordmann A

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Blattmann L

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Gallino A

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Khetari R

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Martina B

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Müller P

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Plebani G

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Schmid H

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Battegay E

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Internal Medicine

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

309-316

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Use of lipid-lowering medication in patients with acute myocardial infarction (Worcester Heart Attack Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

A case-management system for coronary risk factor modification after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Secondary prevention after acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Coronary risk factors in women six months after coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Inadequate management of hyperlipidaemia after coronary bypass surgery shown by medical audit

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Improving care with nurse case managers: practical aspects of designing lipid clinics

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Serum lipids four weeks after acute myocardial infarction are a valid basis for lipid lowering intervention in patients receiving thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

Persistence of use of lipid-lowering medications: a cross-national study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2800%2900110-2

7 January 2021

10.1016/S0953-6205(00)00110-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113654%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference